Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DASH Trial: DS-8201a and AZD6738 in Advanced Solid Tumors With HER2 Expression
NCT04704661Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2021
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ceralasertib in solid tumor, sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events up to 5 years, Recommended phase 2 dose and 1 more. Started Aug 2021; status: active, not recruiting.
02
Drugs
ceralasertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04704661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04704661.